Phase IIb clinical results of antisense oligonucleotide therapy positively significantly reduce blood lipid levels

Article source: Medical Rubik's Cube Info

Author: Shi Bei

On November 24, Ionis announced that the vupanorsen (IONIS-ANGPTL3-LRx) jointly developed with Pfizer has achieved positive results in the Phase IIb study

ANGPTL3 protein is a key regulator of triglyceride and cholesterol metabolism

This global multicenter, double-blind, placebo-controlled Phase IIb RANSLATE-TIMI 70 study enrolled 286 dyslipidemia patients (≥40 years old, non-HDL-C (≥100 mg/dL) and TG (150-500 mg) /dL) is elevated and is receiving a stable dose of statins)

The results showed that compared with placebo, at week 24, subjects in all dose groups of vupanorsen achieved a statistically significant reduction in non-HDL-C levels, reaching the primary endpoint

In terms of safety, the most common adverse event was an injection site reaction, which most often occurred in the highest dose group of vupanorsen

Vupanorsen was developed by Ionis through its advanced ligand-conjugated antisense (LICA) technology